Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique-Hopitaux de Paris, Sorbonne Universite
InventorsDavid Klatzmann, David Saadoun, Patrice Cacoub, Michéle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
Claims20
A method for treating systemic lupus erythematous erythematosus, the method comprising:
- subcutaneously administering to a human subject in need thereof an effective amount of interleukin-2 (IL-2) at a dose of no more than between 0.1 MIU/day and 3.5 MIU/day, wherein the IL-2 is administered in a first course of treatment followed by a maintenance dose, wherein the first course of treatment consists of an administration of the IL-2 once per day for at least 3 consecutive days, and wherein the maintenance dose is given to the human subject once a week, once a month, or twice a month.
A method for stimulating regulatory T lymphocytes (Tregs) in a human subject suffering from systemic lupus erythematosus (SLE), the method comprising:
- subcutaneously administering to the subject an effective amount of interleukin-2 (IL-2) at a dose of between 0.1 MIU/day and 3.5 MIU/day, wherein the IL-2 is administered in a first course of treatment followed by a maintenance dose, wherein the first course of treatment consists of an administration of the IL-2 once per day for at least 3 days, and wherein the maintenance dose is given to the human subject once a week, once a month, or twice a month.
Dependencies are inferred from the claim text.